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ABSTRACT
The management of chronic myelogenous leukaemia (CML)
has undergone a major change over the past 5 years. All newly
diagnosed patients of CML are candidates for imatinib mesylate
therapy. Almost 95% of patients with early chronic phase
CML achieve complete haematological remission (CHR) and
nearly 80% achieve complete cytogenetic response (CGR;
0% Philadelphia [Ph] chromosome-positive metaphases).
These responses are stable in most patients with a risk of
relapse of 4%–6% per year. For patients with advanced CML
(accelerated phase and blast crisis), achievement of CHR and
major (complete and partial) CGR occurs in 25%–37% and
10%–30% of patients, respectively. Most investigators agree
that patients who fail to achieve CHR by 12 weeks, have
partial cytogenetic response (<35% Ph-positive metaphases)
at 12 months, have CGR by 18 months, who relapse after
initial response to imatinib, and those with a high Sokal score
or in an advanced phase of CML should be considered for
allogeneic stem cell transplantation (SCT). Despite Ph negativity
with imatinib treatment, most patients continue to remain
BCR–ABL positive on molecular studies, and require treatment
indefinitely. Identification of patients at high risk for relapse
and understanding the mechanisms to unravel resistance to
imatinib are current areas of active research.
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INTRODUCTION
Chronic myelogenous leukaemia (CML) is a clonal myelo-
proliferative disorder of the pluripotent stem cell. Its incidence is
1 per 100 000 population in the West.1 The true incidence of CML
in India is not available. According to 6 population-based cancer
registries (covering <0.3% of the total population), the incidence
of CML in India varies from 0.8 to 2.2 per 100 000 population for
men and from 0.6 to 1.6 per 100 000 population for women.2
Hospital-based studies have reported a higher frequency of CML
ranging from 40% to 82% of all cases of leukaemia among adults.3
The disease is usually characterized by an insidious onset of
symptoms, progressive splenomegaly, marrow hypercellularity,
anaemia, leucocytosis and cytogenetically by the presence of
Philadelphia (Ph) chromosome t(9;22)(q34;q11) in 90%–95% of
patients. The disease follows a biphasic or triphasic course. There
is an initial chronic phase which after an average of 5–5.5 years
may progress to an intermediate phase called accelerated phase
followed by blastic transformation or blast crisis. At the time of
presentation 90%–95% of patients are in the chronic phase while
the remaining may have features of advanced disease.4
CLINICAL AND HAEMATOLOGICAL FEATURES
The median age of onset is 38–40 years in India3 compared to 50
years in the West. There is a slight male preponderance. With
routine screening tests, 5%–15% of patients are diagnosed in the
asymptomatic stage. The presenting symptoms are usually malaise,
fatigue, abdominal fullness, fever, weight loss, abdominal pain
and occasionally easy bruising or bleeding. Splenomegaly is
present in 90% of patients and in one-third of them it is >10 cm in
size. Nearly 25% of patients have hepatomegaly (>2 cm) but
lymphadenopathy is uncommon (<10%) in the chronic phase (CP)
and is confined to 1–2 regions with small lymph nodes. Initial
haematological investigations show a normal haemoglobin, total
leucocyte count (WBC) of 100–300×109/L and platelet count of
200–400×109/L. Differential count shows the myeloid series of
cells in all stages of maturation with <10% myeloblasts and
promyelocytes and a predominance of myelocytes. Basophils are
increased but only 10%–15% of patients have >7% basophils in
the peripheral blood. Frequently, eosinophils are mildly increased.
The bone marrow (BM) is hypercellular and devoid of fat. There
is myeloid hyperplasia with a myeloid-to-erythroid ratio of 10–
30:1. Evidence of focal fibrosis may be seen on reticulin stain in
25%–28% of patients in the chronic phase but increases with
disease progression. The biochemical abnormalities include low
leucocyte alkaline phosphatase (LAP) score, and marked elevation
of serum B12 and B12 binding protein transcobalamine-I.
Hyperuricaemia related to increased cell turnover may occur
prior to therapy and may be exacerbated by treatment. The LAP
score may increase with infection, clinical remission or onset of
blast crisis.4 Though earlier studies (prior to the 1970s) reported
the clinical and laboratory features of CML patients at diagnosis,
only few studies have reported this aspect in the past 3 decades.
We analysed the clinical and laboratory features of 437 patients
seen at our institute between 1987 and 20005 and compared them
with two other Indian studies (from AIIMS, New Delhi [1975–
1983]6 and from the Cancer Institute, Chennai [1975–1985]7), two
European studies (from Hammersmith Hospital, London [1973–
1995]8 and the German CML Study Group [1983–1991]9) and a
study from North America10 (Table I).
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ACCELERATED PHASE/BLAST CRISIS
With conventional treatment CP progresses to an accelerated
phase (AP) that lasts for 1–1.5 years and is followed by a blast
crisis (BC). In 20%–25% of patients, the transition to BC may be
without an intermediate AP. The criteria used to define AP are
presence of 10%–19% blasts in the peripheral blood (PB) and/or
bone marrow (BM), >20% basophils in the PB or BM, platelet
count <100 000/cmm unrelated to therapy, or platelet count
>1 000 000 unresponsive to therapy, cytogenetic evolution with
new abnormalities in addition to the Philadelphia chromosome
(double Ph chromosome, isochromosome 17 and trisomy of
chromosomes 8, 19 or 21), and p53 mutations or deletions,
increasing splenomegaly or WBC count, unresponsive to therapy.11
BC is a terminal event in 70% of patients and is characterized by
the above features as well as >30% blasts in the PB/BM.4,11
Occasionally, extramedullary blastic infiltrates in the lymph
nodes, bone or skin may precede BC in the BM. Phenotypically,
blasts are mainly myeloblastic (60%), lymphoblastic (20%)
and undifferentiated (10%–15%). Rarely, there may be erythro-
blastic, megakaryocytic or mixed transformation.4,11 Focal myelo-
fibrosis may be seen in up to 30% of patients at presentation.
Increasing myelofibrosis on serial BM biopsies may be associated
with AP/BC.12
MOLECULAR BIOLOGY
The Ph chromosome results from reciprocal translocation between
the long arm of chromosomes 9 and 22.13 Cell synchronization and
high resolution banding techniques have identified the chromosome
breakpoints as t(9;22)(q34.1:11.2).14 The Ph chromosome is also
found in 20%–25% of adults and 5% of children with acute
TABLE I. Clinical and laboratory features of patients with chronic myelogenous leukaemia in different studies
Characteristic Kumar et al.5 Prabhu et al.6 Kumar et al.7 Savage et al.8 Hehlmann et al.9 Kantarjian et al.*10
Period of study 1989–2000 1975–83 1975–85 1973–95 1983–91 1999–2000
No. of patients 437 152 160 430 513 454
Chronic/accelerated 88.5/11.5 93.4/6.6 – 93.3/6.7 – 94/6
phase, blast crisis (%)
M:F 1.6:1 1.4:1 1.7:1 1.4:1 1.4:1 1.5:1
Median (range) age in years 35 (8–75) 36.5 (12–65) 38 (11–75) 34 (5–62) 47.6 (17–85) 57 (18–81)
Median (range) duration of 4 (3–120) nr 3 (1–36) 3 (0–36) nr nr
symptoms in months
Asymptomatic (%) 5.3 3.9 7.5 20.3 nr nr
Symptoms (%)
Weakness, malaise, fatigue 61.7 60 56.3 33.5 62.8 nr
Abdominal mass 53.7 54 52.5 14.8 33.7
Fever 54.5 31 30.6 0.9 18.3
Weight loss 24.2 – 27 20 20.5
Bleeding 6.3 8 17 21.3 –
Signs
Splenomegaly (%) 95.2 91.4 89.4 75.8 71.3 17.7
>10 cm (%) 32.8 38.2 46.2 8.0 – 2
Hepatomegaly (%) 55.3 88.8 48.1 2.2 49.3 8.4
Lymphadenopathy (%) 16.2 – 16.3 <1.0 19.1 0
Laboratory parameters
Haemoglobin (g/dl) 10 – 9 10.3 12 12.5
Median (range) (3–16.7) – (4.5–11.3) (4.9-16.6) (4.2–17.2) (7.3–17.2)
White cell count (×109/L) 145 – 180 174 166 15.0
Median (range) (1800–980) – (25–500) (5–850) (12–600) (2–260)
Platelet count (×109/L) 280 – 250 430 497 303
Median (range) (20–1631) – (50–3182) (17–3182) (10–3400) (100–2081)
* This study included patients in late chronic phase nr not reported
lymphoblastic leukaemia (ALL) and in 1%–2% of patients with
acute myeloblastic leukaemia.15 In the formation of the Ph
chromosome, the ABL proto-oncogene is translocated from
chromosome 9 (q34.1) to the BCR gene in chromosome 22
(q11.2). The resultant fusion gene BCR–ABL transcribes a chimeric
8.5 mRNA which in turn is translated into a novel protein of p210
kDa termed as p210. The latter, presumably through increased
tyrosine kinase activity changes normal haematopoietic cells into
CML cells in vitro and in vivo.16,17 The activation of multiple
signal transduction pathways in BCR–ABL transformed cells
leads to increased proliferation, reduced growth factor dependence
and apoptosis, and perturbed interaction with the extracellular
matrix and stroma.18
Approximately, 3%–10% of CML patients have cytogenetically
normal leukaemic cells (Ph-negative). A proportion of these
patients (30%–80%) have re-arrangements of the BCR–ABL gene
with the production of an 8.5 kb mRNA and p210 kDa BCR–ABL
protein similar to that in patients with Ph-positive CML. The
clinical outcome of patients who are Ph-negative but BCR–ABL
positive is similar to that of patients with Ph-positive, re-arranged
BCR–ABL, suggesting that they represent a single disease. Ph-
negative patients with absence of BCR–ABL re-arrangement have
a distinct clinical course despite their early resemblance to classical
CML. They eventually develop BM failure (anaemia, thrombo-
cytopenia) accompanied by a markedly increased leukaemia
burden with increased WBC count, organomegaly and
extramedullary disease. Blast transformation generally does not
occur. These are probably cases of myelodysplastic syndrome/
chronic myelomonocytic leukaemia. WHO has defined this
subgroup as ‘myeloproliferative syndrome, unclassifiable’.11
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WORK-UP
The investigations to be done in a newly suspected case of CML are
1. Blood: Haemoglobin, total and differential count, platelet
count
2. Liver and renal function tests, serum uric acid
3. Urine examination
4. Chest X-ray
5. Bone marrow aspiration and biopsy, and cytogenetics for Ph
chromosome
6. Reverse transcriptase polymerase chain reaction (RT-PCR)
for the BCR–ABL gene
Bone marrow (BM) cytogenetic studies must be done for all
patients with CML before initiation of treatment. Marrow
cytogenetics help to identify any unusual translocation or additional
cytogenetic abnormalities. RT-PCR for BCR–ABL at diagnosis
will identify whether the commonly observed e13a2(b2a2) or
e14a2(b3a2) transcripts are present, or one of the less common
fusion transcripts that are not amplified by the standard primer
sets. If BM examination is not feasible, fluorescence in situ
hybridization (FISH) on a PB specimen using dual probes for the
BCR and ABL gene is a useful but secondary method of confirming
the diagnosis. This may detect cytogenetically silent BCR–ABL
gene re-arrangements and deletions in the derivatives 9q+. FISH
is considerably less sensitive than RT-PCR and should not replace
it.19,20
TREATMENT
Though CML was described more than 100 years ago, Fowler
solution21 (arsenic trioxide in potassium bicarbonate) and splenic
radiation22 were the only treatment options available till the 1950s.
Busulphan, an alkylating agent, was introduced in 1954 and was
effective in controlling leucocytosis. However, in view of its
toxicity—bone marrow aplasia (1%–3%), hyperpigmentation and
pulmonary fibrosis, and inferior survival compared to
hydroxyurea—it is used only as part of high dose chemotherapy
along with cyclophosphamide in the setting of haemopoietic stem
cell transplantation (SCT).23 Hydroxyurea, introduced in the late
1960s, has a favourable toxicity profile and is effective in
controlling the white cell count. Recombinant interferon-α
(IFN-α) became available in the early 1990s and was superior to
both busulphan and hydroxyurea in attaining complete
haematological remission (CHR), complete cytogenetic response
(CGR) and prolonging survival. Over the past 25 years, experience
with allogeneic haemopoietic SCT from an HLA-matched sibling
or an unrelated donor suggests that it is the only potentially
curative treatment for CML. Its limitations are the availability of
a matched sibling donor in less than one-third of patients and the
potential morbidity (acute and chronic graft-versus-host disease)
and mortality (5%–15%). Imatinib mesylate (STI-571 or Gleevec)
was approved for use in May 2001 and has revolutionized the
management of CML.24 A comparison of hydroxyurea, IFN-α and
imatinib mesylate is given in Table II.
Hydroxyurea
It is an S phase agent and acts by inhibiting DNA synthesis. The
drug has a rapid onset and short duration of action. Therefore, it
controls the white cell count without marked or prolonged
myelosuppression. It is usually given in doses of 0.5–2.0 g per day
in 2 divided doses. This drug has a special role in patients with a
very high white cell count when rapid cytoreduction is essential.
In a newly diagnosed patient of CP-CML (white cell count
>50 000/cmm), hydroxyurea should be started in a dose of 2–3 g
day along with imatinib mesylate. Once the count is <20 000/cmm
hydroxyurea may be stopped.25 In many countries where imatinib
is still not easily available, hydroxyurea is used in intermittent
dose schedules with monitoring of the white cell count.
Interferon alpha (IFN-α)
A number of non-randomized26–33 and randomized studies34–37
have shown the effectiveness of IFN-α in CP-CML (Tables III
and IV). A CHR rate of 60%–80% and a CGR rate of 40%–60%
(including complete CGR in about 10%) is achieved. Five
randomized trials compared the outcome of patients treated with
IFN-α and those treated with hydroxyurea or busulphan.
Subsequently, a meta-analysis of all the randomized trials provided
conclusive evidence that IFN-α significantly prolonged survival
in comparison to hydroxyurea.38,39 The duration of response was
significantly longer in patients with complete CGR. The results
are better if IFN-α is used in early CP (within 1 year of diagnosis)
compared with late CP and in AP/BC (Ph suppression <10%). The
dose of IFN-α varies from 2 to 5 mIU/m2 daily subcutaneously.40
A study comparing 3 mIU of IFN-α three times a week with 5 mIU
daily indicated that the low dose was as effective as and better
tolerated than the high dose.41 Elderly patients (>60 years) tolerate
IFN-α poorly compared with younger patients. The response
criteria42 are given in Table V.
To improve the response rate and survival, IFN-α has been
combined with low dose cytosine arabinoside (Ara-C),
homoharringtonine. Two randomized trials by the French43 and
Italian Groups44 compared low dose Ara-C and IFN-α with
IFN-α alone in CP-CML. The French study showed that the
combination was better than IFN-α alone, both in terms of
cytogenetic response (35% v. 21%) and 5-year survival (70% v.
62%). However, the Italian study failed to demonstrate a survival
benefit (68% v. 65%) despite better cytogenetic response (21% v.
13%) in the combination arm. Only an occasional patient achieves
molecular remission with IFN-α therapy.
The early side-effects of IFN-α include fever, chills and
anorexia. These can be managed symptomatically by giving
TABLE II. Comparison of hydroxyurea, interferon-α and imatinib
mesylate
Factor Hydroxyurea Interferon-α Imatinib mesylate
Mechanism of Ribonucleotide Unknown Selective
action reductase inhibitor inhibitor of
BCR–ABL
Haematological Yes Yes Yes
response
Rapidity Yes No Yes
Cytogenetic No Yes Yes
response
Activity in No No Yes
blastic phase
Survival benefit No Yes Yes
Impact on No Perhaps Unknown
allogeneic bone
marrow transplant
Daily dose 0.5–2 g 3–5 mU/m2 CP 400 mg/day
AP/BC 600 mg/day 
Major toxicity No Yes No
Oral Yes No Yes
administration
Cost Low High Very high 
AP accelerated phase BC blast crisis CP chronic phase
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IFN-α at bed time and paracetamol one hour prior to IFN-α.
Tachyphylaxis develops within 1–2 weeks. The late side-effects
are dose-related and include persistent fatigue, weight loss,
neurotoxicity and occasionally immune-related complications.
IFN-α should be discontinued in patients with severe suicidal
tendencies, parkinsonism, autoimmune haemolytic anaemia, or
severe pulmonary or cardiac toxicity. Dose modification is
indicated in patients with severe central nervous system toxicity,
e.g memory changes, concentration problems and grades II–III
fatigue. The pegylated form of IFN-α given once a week has been
reported to have a similar efficacy and less toxicity in initial
studies.45
Imatinib mesylate (STI-571, Gleevec)
Imatinib mesylate is a 2-phenylaminopyrimidine derivative and is
a BCR–ABL tyrosine kinase signal transduction inhibitor 571
(STI-571). It acts as a competitive inhibitor of the ATP binding
site on the protein and prevents its phosphorylation (and thus its
activity).46 The initial landmark studies by Druker et al. showed
high response rates to imtainib mesylate in patients with advanced
CML47 and those pre-treated with IFN-α.24,47 Recently, O’Brien et
al. (IRIS Group) have reported the results of a randomized study
of 1106 CP-CML patients.48 Patients received imatinib (n=553) or
IFN-α and low dose Ara-C (n=553). At a median follow up of 18
months, the estimated major CGR rate was 87% compared with
34.7% in the IFN-α group. The estimated CGR rate was 76% in
the imatinib group compared to 14.5% in the IFN-α group. This
randomized study confirmed that in terms of CHR, major
cytogenetic response, CGR and the likelihood of progression to
AP/BC, imatinib was superior to IFN-α and low dose Ara-C as
first-line therapy in newly diagnosed CP-CML patients.48 In
addition, patients on imatinib had a better quality of life.49 An
update on the IRIS study published recently showed that at a
median follow up of 42 months, 98% of the patients were in CHR
and 84% had CGR; 75% of the patients were still on imatinib, 9%
had progressed to AP/BC, 6% developed significant toxicity and
9% stopped imatinib due to other reasons.42
Two studies have been reported from India (Table VI).50,51 The
CHR rates in both these studies were similar to those reported
by the IRIS study and from other centres52–54 but the CGR rates
were inferior to those reported by the IRIS trial. The possible
reasons for the low CGR rates in the studies from India could be
inclusion of a large number of patients in late CP and with
advanced disease, and of those pre-treated with IFN-α. There
appears to be a correlation between plasma levels of imatinib and
achievement of CGR.55
TABLE III. Results of interferon (IFN)-α treatment in patients with chronic myelogenous leukaemia
Author (year) n IFN-α dose Haematological response (%) Cytogenetic response (%) Median survival (%)
Complete Partial Complete Partial
Ozer et al. (1993)26 107 5 mU/m2 daily 59 36.4 13 16 52 at 5 years (66 months)
Alimena et al. (1990)27 74 2 v. 5 mU/m2 daily 41.6 – 22.2 na na
Kloke et al. (1993)28 71 4 mU/m2 daily na na 13 13 55 at 5 years
Thaler et al. (1993)29 80* 3.5 mU daily 39 35 5 5 na
Mahon et al. (1994)30 52 5 mU/m2 daily 80.7 17.3 42.5 (20/47) 6.9 (3/47) na
Schofield et al. (1994)31 27 2 mU/m2 thrice a week 70 7 15 – 79 at 2 years,73 at 3 years
Kantarjian et al. (1995)32 274 5 mU/m2 daily 80 7 26 12 63 at 5 years (89 months) 
Kumar et al. (2005)33 114 5 mU daily 31.6 25.4 1.8 28 –
na not available * 74 evaluable for response
TABLE IV. Results of randomized trials of interferon (IFN)-α versus hydroxyurea (HU) /busulphan (Bu)
Author (year) IFN-α HU/Bu Dose of IFN-α Major cytogenetic response (%) 5-year overall survival (%)
IFN-α HU/Bu IFN-α HU/Bu
Italian Study Group (1994)34 218 94/10 5 mU/m2 19 1 60 45
Hehlmann et al. (1994)9 133 194/186 5 mU/m2 6 1/1 58 48/33
Allan et al. (1995)35 293 142/152 5 mU/m2 10 2 50 32
Ohnishi et al. (1995)36 85 0/85 5 mU/m2 15 5 63 37
Benelux Study Group (1998)37 100 95/0 3 mU (total) 16 2 54 54
Hasford et al. (1996)38 640 286/345 – nr nr 57 46/34
nr not reported
TABLE V. Criteria for assessing response in patients with chronic
myeloid leukaemia (adapted from references 20, 42)
Haematological response
Complete
1. Total leucocyte count <10 000/cmm, platelets counts <450 000/cmm
2. Normalization of differential count with no immature forms
(myelocytes, metamyelocytes, promyelocytes and blasts)
3. Disappearance of all clinical signs and symptoms including
splenomegaly
4. No evidence of extramedullary disease
Partial
1. More than 50% decrease in total leucocyte count from pre-treatment
levels to <20 000/cmm
2. Persistence of immature forms on the differential count
3. Persistent splenomegaly
Cytogenetic response (Ph-positive metaphases in bone marrow)*
Complete† 0%
Partial† 1%–35%
Minor 36%–65%
Minimal 66%–95%
No 100%
Molecular response
Major >3 log reduction of BCR–ABL mRNA
Complete Negative by RT-PCR
* based on the analysis of at least 20 metaphases
† major cytogenetic response includes complete and partial response
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Dose. Patients in CP-CML should receive imatinib 400 mg or
250 mg/m2 as a single daily dose. However, in those with
advanced disease a higher dose (600 mg daily) is used. Kantarjian
et al. treated 114 newly diagnosed CP-CML patients using
higher doses of imatinib—400 mg twice daily compared to 400
mg daily in the standard arm. At a median follow up of 15
months, 96% (109/114) achieved major cytogenetic response
with 90% CGR. In 63% of patients, BCR–ABL transcripts
decreased to <0.05% by quantitative PCR and were undetectable
in 28% of them.56 An update on this study was presented
recently;57 among 171 evaluable patients, the CGR rate was 90%
compared with 78% in the standard arm (p<0.03). At 12 months,
major molecular response was noted in 54% compared with 24%
in the standard arm (p<0.001); 25 patients (4%) progressed
compared with 8% in the standard arm (p<0.05). However, the
overall survival was similar in both arms, 99% v. 98% (p=0.24).
High doses of imatinib were associated with more frequent
grades III–IV myelosuppression and 39% of patients required
dose reduction.56,57 Phase I–II studies have explored combinations
of imatinib and low dose Ara-C58 or imatinib and pegylated
IFN59 in an attempt to achieve higher response rates. Recent data
of two new drugs—BMS 354825 (dasatinib) and AMN107
(nilotinib) with potent ABL kinase inhibitor activity are
promising60,61 and combining either of them with imatinib may
prove to be superior than imatinib alone.62
Toxicity. In the IRIS trial, the common late side-effects (at 18
months) were neutropenia (3.8%), thrombocytopenia (2.1%),
anaemia (1%) and other drug-related grades III–IV toxicities in
5.8% of patients. Common non-haematological toxicities of
imatinib are weight gain (median time 4–5 months), hypopigmen-
tation of exposed parts63 and skin toxicity. Transient reversible
elevation of liver enzymes may occur in 10%–20% of patients.
Occasionally, tumour lysis syndrome64 and bone marrow aplasia65
have been reported.
Monitoring treatment. Weekly blood counts for the first 4
weeks, twice weekly during the second month, then at 2–4-week
intervals are recommended. This helps to identify non-responders
as well as those who develop major toxicities requiring dose
adjustment and/or granulocyte colony stimulating factor (G-CSF)
support. Renal and liver function tests must be done initially 2-
weekly for 1–2 months and then monthly.42
Monitoring response. Bone marrow cytogenetics is the gold
standard for monitoring response. It has been suggested that
circulating BCR–ABL transcript numbers should be measured by
RT-PCR. For monitoring cytogenetic response, bone marrow
cytogenetic studies must be done at 3, 6, 9 and 12 months (Table
VII). In patients who achieve significant response, quantitative
PCR studies to monitor BCR–ABL transcripts may be done from
PB. Almost all patients (>95%) achieve CHR by 12 weeks of
imatinib therapy. More than 80% of patients achieve CGR after
12 months of imatinib therapy. Response rates are lower in patients
previously treated with IFN-α. Patients who achieve some degree
of CGR at 3 or 6 months are more likely to achieve CGR at
12 months. About 5%–15% of patients on imatinib achieve complete
molecular remission. As patients who achieve CGR or major
molecular remission become Ph-positive or BCR–ABL positive
after stopping imatinib, it is recommended that in responders
imatinib should be continued indefinitely.42
Despite achieving high CGR rates with imatinib, why patients
remain positive for BCR–ABL is not entirely clear. It has been
suggested that imatinib primarily inhibits proliferation of BCR–
ABL positive primitive progenitor cells without induction of
apoptosis. Hence, imatinib may be able to prevent stem cell
proliferation but unable to eliminate quiescent cells.66
Imatinib resistance. Primary haematological resistance (defined
as failure to obtain CHR) is seen in <5% of early CP-CML patients
(disease duration <6 months).67 Primary cytogenetic resistance
(failure to achieve major CGR) after 6 months of treatment or
CGR after 12 months of therapy is more common and is seen in
about 15% of CP-CML patients. In the IRIS study, 16% of patients
developed secondary resistance (defined as loss of haematological
or cytogenetic response) at 42 months of follow up. This was low
compared with 26% in the IFN-α and low dose Ara-C group at 48
months of follow up.42,68 The frequency of resistance is higher in
patients with AP (73%) and BC (95%). The common mechanisms
of secondary resistance include mutations in the BCR–ABL kinase
domain (50%–90%), overexpression of BCR–ABL (10%) typically
through gene amplification,69,70 or acquisition of additional Ph
chromosomes. Strategies to overcome imatinib resistance include
(i) dose escalation56,57 (higher doses of imatinib can overcome
resistance in a subset of patients but these responses are not
durable); (ii) combining it with conventional cytotoxic drugs with
established activity in CML (Ara-C,58 homoharringtonine,
interferon-α59) has been studied in phase I–II trials; (iii) treatment
TABLE VI. Comparison of results of imatinib mesylate in patients with chronic myelogenous leukaemia
Item Arora et al. (2005)50 Deshmukh et al. (2005)51 Lahaye et al. (2005)54 O’Brien et al. (2003)48
n 110 174 300 553
Median age (range) in years CP 38 (11–65) 38 (4–79) CP 56(18.5–77) 50 (18–70)
AP/BC 36 (13–60)
Sex (M:F) 84:34 122:52 78:61 341:212
Median (range) interval from diagnosis to CP 25 (2–204) 36 31 (2–312) 2.1
starting imatinib in months AP/BC 37 (6.5–120)
Disease status CP/AP/BC 79/23/16 97/47/30 139/80/81 553
Complete haematological response (%) CP 95.8 Early CP 100 CP 97 95.3
AP+BC 35 Late CP 89 AP 61
AP 55.5 BC 18
BC 36.7
Median time for CHR 21 days (7–122) nr nr 1 month
Complete/major cytogenetic response (%) CP 24.5/30 Early CP 20.8/41.7 CP 49/61 73.8/85.2
AP+BC 6.7/13.4 Late CP 19/27 AP 26/31
AP 6.4/15 BC 8/12
BC 13/10
CP chronic phase AP accelerated phase BC blast crisis nr not reported
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with ABL kinase inhibitors, e.g. dasatinib (BMS-354825) and
nilotinib (AMN 107) (Table VIII).60,61
These data indicate that both agents have significant activity in
patients with CML resistant or intolerant to imatinib. Whether a
combination of imatinib with dasatinib or nilotinib would be more
effective in the primary treatment of CML needs to be studied.
Allogeneic bone marrow/blood stem cell transplantation
Allogeneic haemopoietic SCT is a potentially curative treatment
for CML and results in sustained molecular remission (RT-PCR
negative) in a majority of patients. Such cures presumably result
from the combined effects of high dose chemotherapy and the
graft-versus-leukaemia effect mediated by donor-derived T
lymphocytes.70 Gratwohl et al. for the European Bone Marrow
TABLE VII. Guidelines for monitoring response to imatinib
(adapted from references 19, 42)
Investigation Interval
Blood counts Weekly during first 4 weeks, 2-weekly
for next 8 weeks, then 2–4-weekly
Bone marrow cytogenetics At baseline, then at 3, 6, 9 and
12 months, then every 12 months in
responders
BCR–ABL transcripts numbers At diagnosis, and can be done at
3-month intervals in complete
cytogenetic responders 
Fluorescent in situ From peripheral blood at diagnosis if
hybridization bone marrow collection is not feasible.
Less sensitive compared to RT-PCR in
complete cytogenetic response
RT-PCR reverse transcriptase polymerase chain reaction
Transplant Registry (EBMTR) have reported a risk-based scoring
system (called EURO score) based on 5 principal prognostic
factors (donor type, stage of CML, recipient’s age, donor–recipient
sex combination and interval from diagnosis). Each factor was
scored 0, 1 or 2 (0=most favourable, 2=least favourable). The
aggregate score calculated in this manner correlated well with the
actual survival.76 This approach appears useful for a clinician to
make recommendations and for the patient to decide whether or
not to undergo allogeneic SCT.76 This has been validated in a large
number of patients in a recent study by the EBMTR (Table IX).77
About 50% of CP-CML patients achieve long term leukaemia-
free survival (LFS) following transplant; LFS is higher for young
patients and those with a EURO risk score of 0–1 (60%–70%).
The outcome of HLA-matched sibling transplants is superior
compared to matched unrelated donor transplants. For patients
with AP and BC allogeneic SCT results in a disease-free survival
rate of 15%–25% and <15%, respectively.
CML is highly susceptible to a graft-versus-leukaemia effect.
Patients who relapse after allogeneic SCT can be treated
successfully using donor lymphocyte infusion (DLI) without pre-
transplant conditioning. For patients with molecular or cytogenetic
relapse of CML, the complete remission rate is 85%–90%, and
most responses are sustained.82–84 These observations have led to
the use of non-myeloablative or less intensive allotransplants,
especially for patients above 45–50 years of age. Patients may
engraft with mixed chimerism which gradually converts to full
donor chimerism with the use of DLI.85
Excellent and rapid responses achieved with imatinib have led
to a dilemma for patients and physicians: whether to delay
allogeneic SCT (in view of its potential morbidity and mortality).
Imatinib results in complete CGR in 75%–80% of CP patients but
TABLE VIII. Studies on the treatment of patients with imatinib resistance using dasatinib and nilotinib
Author CML phase n Response Grade III–IV toxicity
Haematological Cytogenetic
Dasatinib
Talpaz et al.60 CP 40 Complete 37/40 (45) Neutropenia, pleural effusion, oedema,
AP/BC 44 Major 31/44 (25) headache
Ph+ve, ALL
Talpaz et al.71 AP 107 Major 63/107 (59) Major 33 (32) Thrombocytopenia (79), neutropenia (69),
START-A study evaluable Complete 35 (33) Complete 23 (22) diarrhoea (46), peripheral oedema (27),
No evidence of Partial 10 (10) pleural effusion (16), rashes (8),
leukaemia 28 (26) gastrointestinal bleed (7)
Coutre et al.72 L-BC 42 Major (31) Major (50) Thrombocytopenia (82), neutropenia (76), 
START-L study Ph+ve ALL 36 Complete (26) diarrhoea (30), nausea (23), fatigue (19); 
Major (42) Major (58) rash (17), pleural effusion (13)
Complete (31)
Estrov et al.73 Nilotinib failed CML CP 1 Complete 1/1 Not given Not given
AP 5 Complete 4/5
BC 5 CP 1, BMCR 1
2nd CP 1
Cortes et al.74 Myeloid BC 74 HR 39 (53) Major 22 (32) Diarrhoea (7), pleural effusion (9),
START-B study Major 24 (32) Complete 20 (27) nausea (4), peripheral oedema (14),
Complete 18 (24) rash (11)
No leukaemia 6 (8)
Nilotinib
Kantarjian et al.61 BC/AP/CP 33/46/12 13/33; 33/46; 11/12 9/33; 22/46 Neutropenia, diarrhoea, thrombocytopenia
Le Coutre et al.75 AP 22 HR 14 (64) Complete 1 Thrombocytopenia (27), neutropenia (18)
Complete 10 (45) Partial 1
No leukaemia 3 (14) Minimal 3
CP-1 Minor 1
Values in parentheses are percentages CP chronic phase AP accelerated phase BC blast crisis L–BC lymphoid blast crisis HR haematological response
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molecular CR in only 5%–15%. Further, the depth of molecular
CR is inferior compared with those achieved after allogeneic
SCT.42 Other limitations of imatinib include prolonged treatment
(currently lifelong); in 6%–9% patients the disease progresses
even after an excellent response, sometimes without early
warning;42 and the high cost of the drug. Many investigators are of
the opinion that for young patients (<30–35 years) with an HLA-
identical sibling donor and a low risk EURO score (0–2) allogeneic
SCT may be offered as the primary treatment. For those in a higher
age group or who do not have an HLA-identical match, imatinib
should be used. Patients who achieve CHR by 12 weeks and major
cytogenetic response by 12 months or CGR by 18 months of
imatinib therapy should be continued on imatinib.19,20 Patients
who fail to achieve these milestones or have evidence of loss of
response or imatinib resistance after an initial response, should be
considered for allogeneic SCT. Patients with a high Sokal score
should be considered for SCT in the beginning. Similarly, children
regardless of Sokal score should be considered for allogeneic
SCT. Since the results of imatinib therapy in advanced stages of
CML are poor, such patients should be considered for allogeneic
SCT at the earliest (Fig. 1).42
CML vaccine
The junctional region of p210 bcr–abl contains amino acid
sequences that are not expressed in a normal cell. From these
amino acid sequences peptides can be synthesized which can elicit
HLA class I restricted cytotoxic T lymphocytes and class II
responses.
Recently, Bocchia et al. in a phase II multicentric trial have
shown that a vaccine targeting the BCR–ABL derived p210 fusion
protein can further reduce persistent residual disease in patients
on conventional treatment for CML and elicits a tumour-specific
immune response.86 These findings need confirmation in a larger
number of patients. The dose (of peptide) and schedule of
administration of the vaccine also need to be worked out.87
CONCLUSION
The introduction of imatinib mesylate has revolutionized the
management of CML. Imatinib treatment is associated with higher
haematological and cytogenetic response rates. While most of
these responses are stable, resistance to treatment after an initial
response can occur, more so in patients in advanced stages of the
disease. Most patients continue to be positive for BCR–ABL by
RT-PCR, indicating persistence of disease. The option of allogeneic
SCT must be considered carefully after evaluating the response to
imatinib at important time points and taking patient preference
into account.42
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Obituaries
Many doctors in India practise medicine in difficult areas under trying
circumstances and resist the attraction of better prospects in western
countries and in the Middle East. They die without their contributions to our
country being acknowledged.
The National Medical Journal of India wishes to recognize the efforts of
these doctors. We invite short accounts of the life and work of a recently
deceased colleague by a friend, student or relative. The account in about
500 to 1000 words should describe his or her education and training and
highlight the achievements as well as disappointments. A photograph
should accompany the obituary.
—Editor
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